Division of Cardiology, Department of Internal Medicine III, Goethe University Frankfurt, Germany; German Centre for Cardiovascular Research (DZHK), partner site RheinMain, Frankfurt, Germany.
Division of Nephrology, Department of Medicine, University of Würzburg, Germany.
Int J Cardiol. 2017 Oct 15;245:6-12. doi: 10.1016/j.ijcard.2017.07.086. Epub 2017 Jul 25.
Impaired renal function, reflected by estimated glomerular filtration rate (eGFR) or cystatin C, is a strong risk predictor in the presence of acute myocardial infarction (AMI). Urinary neutrophil gelatinase-associated lipocalin (uNGAL) is an early marker of acute kidney injury. uNGAL might also be a good predictor of outcome in patients with cardiovascular disease. Aim of the present study was to evaluate the prognostic value of uNGAL compared to eGFR and cystatin C in patients with suspected AMI.
1818 patients were enrolled with suspected AMI. Follow-up information on the combined endpoint of death or non-fatal myocardial infarction was obtained 6months after enrolment and was available in 1804 patients. 63 events (3.5%) were registered.
While cystatin C and eGFR were strong risk predictors for the primary endpoint even adjusted for several variables, uNGAL was not independently associated with outcome: When applied continuously uNGAL was associated with outcome but did not remain a statistically significant predictor after several adjustments (i.e. eGFR). By adding cystatin C or uNGAL to GRACE risk score variables, only cystatin C could improve the predictive value while uNGAL showed no improvement.
We could show that cystatin C is an independent risk predictor in patients with suspected AMI and cystatin C can add improvement to the commonly used GRACE risk score. In contrast uNGAL is not independently associated with outcome and seems not to add further prognostic information to GRACE risk score.
肾小球滤过率(eGFR)或胱抑素 C 反映的肾功能受损是急性心肌梗死(AMI)患者的一个强烈的风险预测指标。尿中性粒细胞明胶酶相关脂质运载蛋白(uNGAL)是急性肾损伤的早期标志物。uNGAL 可能也是心血管疾病患者预后的良好预测指标。本研究旨在评估 uNGAL 与 eGFR 和胱抑素 C 在疑似 AMI 患者中的预后价值。
共纳入 1818 例疑似 AMI 患者。在入组后 6 个月获得了死亡或非致死性心肌梗死联合终点的随访信息,其中 1804 例患者的信息可用。共登记了 63 例事件(3.5%)。
尽管胱抑素 C 和 eGFR 是主要终点的强风险预测指标,即使在调整了几个变量后也是如此,但 uNGAL 与结果没有独立关联:当连续应用时,uNGAL 与结果相关,但在进行多次调整后(即 eGFR)不再是统计学上显著的预测指标。当将胱抑素 C 或 uNGAL 添加到 GRACE 风险评分变量中时,只有胱抑素 C 可以改善预测价值,而 uNGAL 没有显示出改善。
我们可以证明胱抑素 C 是疑似 AMI 患者的独立风险预测指标,胱抑素 C 可以提高常用的 GRACE 风险评分的预测价值。相比之下,uNGAL 与结果没有独立关联,似乎不能为 GRACE 风险评分提供额外的预后信息。